Brief: VBI Vaccines To Present New Overall Survival Data From Phase 2A Study In Recurrent GBM
01/12/2021 21:51
Dec 1 (Reuters) - VBI Vaccines Inc VBIV.O :
* VBI VACCINES TO PRESENT NEW OVERALL SURVIVAL DATA FROM
PHASE 2A
STUDY IN RECURRENT GBM AT THE WORLD VACCINE & IMMUNOTHERAPY
CONGRESS 2021
* VBI VACCINES INC - UPDATED 12-MONTH AND 18-MONTH OVERALL
SURVIVAL DATA DEMONSTRATE CONTINUED IMPROVEMENTS COMPARED TO
HISTORICAL CONTROLS
* VBI VACCINES - 1 PATIENT REMAINING ON PROTOCOL ACHIEVED
PROGRESSION-FREE SURVIVAL BEYOND 86 WEEKS, DEMONSTRATING 93%
TUMOR REDUCTION RELATIVE TO BASELINE
Source text for Eikon: ID:nBw4m43jTa
Further company coverage: VBIV.O
Recent news on VBI Vaccines
See all newsBrief: VBI Vaccines Provides Update On Its Restructuring Proceedings
Brief: Vbi Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2B Study Of Vbi-1901 In Recurrent Glioblastoma Patients
VBI Vaccines Inc reports results for the quarter ended in March - Earnings Summary
Brief: VBI Vaccines Says Entered At Market Offering Deal For Gross Proceeds Of Up To $8.5 Mln
Brief: VBI Vaccines Q1 Adjusted EPS USD -0.55